Not only replace stroke with CHF but to have SGLT2's in conjunction with ABL. As Dr Ray suggested in the video, increasing the bio markers to about 150 as well. In that scenario if they got close to the same 66% RRR as they did with that group in BoM they may have to halt a trial like that early for ethical reasons and put all patients on ABL/SGLT2 combination. Since they already have a good safety profile from BoM, that may be the shortest most economical route to market.

Who are the companies that make SGLT2's? One of these companies would stand to benefit the most from some form of partnership or outright purchase.

Jardiance had about 50% of that market at the end of 2018. We'll see updated numbers for market share in the near future. 

tada